Micro Chamber Mixing Nucleic Acids for Rapid In Vivo Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids in vivo face challenges such as instability of cationic lipid formulations, limited targeting specificity, high nuclease degradation, and toxicity issues, resulting in ineffective delivery to cells, particularly cancer cells and across biological barriers like the blood-brain barrier.
Innovation Solution
A micro chamber system that rapidly mixes cationic lipids and nucleic acids and directs the resulting particles into an injection needle within less than one second, significantly reducing incubation time and eliminating the need for nuclease-protective groups, enabling effective delivery to various organs and cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipid formulations are used for nucleic acid delivery, then cell uptake and transfection efficiency are improved, but formulation stability and shelf life deteriorate due to aggregation
Solution Approach 1:
The patent changes the physical-chemical parameters of the cationic lipid formulation by controlling the charge ratio between cationic lipids and nucleic acids, optimizing particle size distribution, and adjusting formulation composition to prevent aggregation while maintaining transfection efficiency. This resolves the contradiction by finding optimal parameter ranges that satisfy both stability and productivity requirements.
2Productivity
If nucleic acids are delivered in vivo, then therapeutic potential is improved, but nuclease degradation increases causing loss of therapeutic molecule
Solution Approach 1:
The patent uses cationic lipid particles as intermediary carriers that protect nucleic acids from nuclease degradation in vivo. The lipid formulation acts as a protective vehicle that shields the therapeutic nucleic acid from enzymatic degradation while facilitating its delivery to target cells, thereby resolving the contradiction between delivery efficiency and molecular stability.
3Measurement precision
If ligands are attached to nucleic acids for organ targeting, then targeting specificity is improved, but toxicity increases due to endosomal disruption requirements
Solution Approach 1:
The patent optimizes the charge ratio and physical properties of the cationic lipid particles to achieve effective targeting and cell uptake without requiring high concentrations of endosomolytic agents. By carefully controlling formulation parameters, the patent reduces toxicity while maintaining targeting specificity, resolving the contradiction between these two critical factors.
4Reliability
If complexation with cationic liposomes is used, then nuclease protection is improved, but organ-specific targeting is lost and macrophage targeting occurs with toxicological effects
Solution Approach 1:
The patent modifies the cationic lipid formulation parameters including charge ratio, particle size, and composition to reduce non-specific macrophage uptake and associated toxicological effects while maintaining nuclease protection. By optimizing these parameters, the patent achieves better tissue distribution and reduced toxicity compared to traditional liposomal formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves efficient and targeted delivery of nucleic acids to cells in normal organs and cancer cells, as demonstrated by nuclear co-localization of siRNA signals, with no observed toxicity, and allows for delivery to brain neurons, overcoming previous limitations of in vivo nucleic acid delivery.
Implementation Method 1
rapidly mixes cationic lipids and nucleic acids
Implementation Method 2
rapidly mixes cationic lipids and nucleic acids
Implementation Method 3
cationic lipids and nucleic acids which are then directed into an injection needle... cationic polymer-nucleic acid compounds
Data Source
AI summary
A process is described for transfecting nucleic acids into cells in vivo by mixing transfection reagents and the nucleic acids immediately prior to injection. The process comprises introducing the transfection reagents and the nucleic acids into a mixing chamber by a first portal for introducing the transfection reagents, a second portal for introducing the nucleic acids where the transfection reagents and nucleic acids are mixed together to form particles and pushing the particles through an injection portal into a mammal in less than 1 second after introduction thereby transfecting cells in the mammal.